Sandoz Slams ‘Desperate’ J&J Attempt To Block US Private-Label Stelara Rival

Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”